-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Biological drugs are characterized by high pharmacological activity and small toxic and side effects, and have great potential in the treatment of cancer, AIDS, coronary heart disease, diabetes and other diseases
.
In recent years, with the aging of the population and the continuous upgrading of consumption, the biopharmaceutical market has continued to expand and burst out with huge development potential, becoming a major sub-industry with rapid development in the pharmaceutical industry
.
The global biopharmaceutical market size is expected to rise from US$202 billion in 2016 to US$326 billion in 2022, with a compound annual growth rate of 8.
3%
.
The market size of China will maintain a compound annual growth rate of 16.
4% from 152.
7 billion yuan in 2016, and will exceed 400 billion yuan by 2022
.
Pharmaceutical Equipment (Source: Pharmaceutical Network) Domestic biopharmaceutical industry ushered in an outbreak In the past, China's biopharmaceutical market accounted for about 20-30% of the entire Chinese pharmaceutical market
.
In recent years, affected by various factors such as policies, talents, capital, etc.
, China's biopharmaceutical industry has ushered in an outbreak.
In 2020, the scale of China's biopharmaceutical market has reached 387 billion yuan, and the proportion of China's drug market is also increasing
.
There are more than 100 domestic pharmaceutical companies deploying biosimilars, and representative companies include Qilu Pharmaceutical, Henlius, Chia Tai Tianqing, Innovent,
etc.
Among them, following the listing of Fuhong Henlius' Rituximab Injection, Bio-Tech Biotech's Adalimumab Injection, Hisun Pharmaceutical's Adalimumab Injection, Qilu Pharmaceutical's Bevacizumab A large number of biosimilars independently developed by domestic companies, such as injections, have been approved for marketing
.
At present, the number of biosimilar R&D pipelines in China ranks first in the world, a large number of research projects are ready to go, and the market competition is becoming more and more fierce
.
At the same time, with the accelerated launch of biopharmaceuticals, the fixed asset investment of many biopharmaceutical companies has shown a trend of rapid growth
.
For example, in 2021, Qilu Pharmaceutical will continue to increase investment in research and development, with a total investment of 3.
32 billion yuan in research and development, a year-on-year increase of 25.
3%
.
The company plans to continue to increase investment in fixed assets in the next step, and continue to develop "global new" and "global good" domestic drugs; Henlius will increase the company's production capacity and meet the commercial production needs of biosimilars and bio-innovative drug products.
, In recent years, the investment in fixed assets has also increased significantly, which is used to build a biomedical industrialization base
.
The development of the pharmaceutical equipment industry will enter a new spring With the vigorous development of the domestic biopharmaceutical industry and the growth of corporate fixed asset investment, the development of China's pharmaceutical equipment industry is expected to enter a new spring
.
Data shows that in 2020, the global biopharmaceutical equipment and consumables market will reach approximately US$18.
7 billion.
Frost & Sullivan expects the global equipment and consumables market to maintain a growth rate of 8%-10% in the next five years
.
The market size of China's biopharmaceutical equipment and consumables is about 17.
5 billion yuan
.
As a rapidly developing and potential market, China's biopharmaceutical equipment and consumables market has very broad prospects in the future.
It is expected that the market size is expected to maintain a growth rate of more than 20%
.
It is worth mentioning that due to the high barriers to R&D and production of high-end biopharmaceutical equipment, there are very few domestic enterprises with R&D capabilities for biopharmaceutical production equipment and consumables, mainly including Aoxing Life Technology, Morison International, Tofflon, etc.
The overall percentage of domestic market share is also low
.
In general, at present, China's biopharmaceutical equipment mainly relies on imports, and the overall localization rate is still very low
.
With the development of China's pharmaceutical equipment technology and the continuous increase in R&D investment of pharmaceutical machine companies, some biopharmaceutical equipment such as stainless steel reactors are accelerating the pace of replacing imports, and disposable reaction systems with high technical barriers are also expected in the near future.
Implement import substitution
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
In recent years, with the aging of the population and the continuous upgrading of consumption, the biopharmaceutical market has continued to expand and burst out with huge development potential, becoming a major sub-industry with rapid development in the pharmaceutical industry
.
The global biopharmaceutical market size is expected to rise from US$202 billion in 2016 to US$326 billion in 2022, with a compound annual growth rate of 8.
3%
.
The market size of China will maintain a compound annual growth rate of 16.
4% from 152.
7 billion yuan in 2016, and will exceed 400 billion yuan by 2022
.
Pharmaceutical Equipment (Source: Pharmaceutical Network) Domestic biopharmaceutical industry ushered in an outbreak In the past, China's biopharmaceutical market accounted for about 20-30% of the entire Chinese pharmaceutical market
.
In recent years, affected by various factors such as policies, talents, capital, etc.
, China's biopharmaceutical industry has ushered in an outbreak.
In 2020, the scale of China's biopharmaceutical market has reached 387 billion yuan, and the proportion of China's drug market is also increasing
.
There are more than 100 domestic pharmaceutical companies deploying biosimilars, and representative companies include Qilu Pharmaceutical, Henlius, Chia Tai Tianqing, Innovent,
etc.
Among them, following the listing of Fuhong Henlius' Rituximab Injection, Bio-Tech Biotech's Adalimumab Injection, Hisun Pharmaceutical's Adalimumab Injection, Qilu Pharmaceutical's Bevacizumab A large number of biosimilars independently developed by domestic companies, such as injections, have been approved for marketing
.
At present, the number of biosimilar R&D pipelines in China ranks first in the world, a large number of research projects are ready to go, and the market competition is becoming more and more fierce
.
At the same time, with the accelerated launch of biopharmaceuticals, the fixed asset investment of many biopharmaceutical companies has shown a trend of rapid growth
.
For example, in 2021, Qilu Pharmaceutical will continue to increase investment in research and development, with a total investment of 3.
32 billion yuan in research and development, a year-on-year increase of 25.
3%
.
The company plans to continue to increase investment in fixed assets in the next step, and continue to develop "global new" and "global good" domestic drugs; Henlius will increase the company's production capacity and meet the commercial production needs of biosimilars and bio-innovative drug products.
, In recent years, the investment in fixed assets has also increased significantly, which is used to build a biomedical industrialization base
.
The development of the pharmaceutical equipment industry will enter a new spring With the vigorous development of the domestic biopharmaceutical industry and the growth of corporate fixed asset investment, the development of China's pharmaceutical equipment industry is expected to enter a new spring
.
Data shows that in 2020, the global biopharmaceutical equipment and consumables market will reach approximately US$18.
7 billion.
Frost & Sullivan expects the global equipment and consumables market to maintain a growth rate of 8%-10% in the next five years
.
The market size of China's biopharmaceutical equipment and consumables is about 17.
5 billion yuan
.
As a rapidly developing and potential market, China's biopharmaceutical equipment and consumables market has very broad prospects in the future.
It is expected that the market size is expected to maintain a growth rate of more than 20%
.
It is worth mentioning that due to the high barriers to R&D and production of high-end biopharmaceutical equipment, there are very few domestic enterprises with R&D capabilities for biopharmaceutical production equipment and consumables, mainly including Aoxing Life Technology, Morison International, Tofflon, etc.
The overall percentage of domestic market share is also low
.
In general, at present, China's biopharmaceutical equipment mainly relies on imports, and the overall localization rate is still very low
.
With the development of China's pharmaceutical equipment technology and the continuous increase in R&D investment of pharmaceutical machine companies, some biopharmaceutical equipment such as stainless steel reactors are accelerating the pace of replacing imports, and disposable reaction systems with high technical barriers are also expected in the near future.
Implement import substitution
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
